A post-incorporation study on the use of palivizumab in the Brazilian public health system
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/245656 |
Resumo: | Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials. |
id |
UFRGS-2_6e58c059de47e5516f76e9896204cef0 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/245656 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Batista, Joanna d'Arc LyraFerreira, Maria Angelica PiresXavier, Cilene da SilvaSouza, Ires Tarsila Alves deCruz, Luciane NascimentoPolanczyk, Carisi Anne2022-07-28T04:46:52Z20210036-4665http://hdl.handle.net/10183/245656001145970Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials.application/pdfengRevista do Instituto de Medicina Tropical de São Paulo. São Paulo. Vol. 63 (2021), e5, 8 p.Sistema Único de SaúdeSaúde da criançaPalivizumabVírus sinciciais respiratóriosInfecções por vírus respiratório sincicialRespiratory syncytial virusesInfant healthComparative effectiveness researchA post-incorporation study on the use of palivizumab in the Brazilian public health systeminfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001145970.pdf.txt001145970.pdf.txtExtracted Texttext/plain34381http://www.lume.ufrgs.br/bitstream/10183/245656/2/001145970.pdf.txtaba3e1b1bd65980c4ff06e1b54c1eb0cMD52ORIGINAL001145970.pdfTexto completo (inglês)application/pdf169379http://www.lume.ufrgs.br/bitstream/10183/245656/1/001145970.pdfd9bb8533e2f02fb8318e438f8caa8384MD5110183/2456562023-08-24 03:36:28.733758oai:www.lume.ufrgs.br:10183/245656Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-08-24T06:36:28Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
spellingShingle |
A post-incorporation study on the use of palivizumab in the Brazilian public health system Batista, Joanna d'Arc Lyra Sistema Único de Saúde Saúde da criança Palivizumab Vírus sinciciais respiratórios Infecções por vírus respiratório sincicial Respiratory syncytial viruses Infant health Comparative effectiveness research |
title_short |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_full |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_fullStr |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_full_unstemmed |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_sort |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
author |
Batista, Joanna d'Arc Lyra |
author_facet |
Batista, Joanna d'Arc Lyra Ferreira, Maria Angelica Pires Xavier, Cilene da Silva Souza, Ires Tarsila Alves de Cruz, Luciane Nascimento Polanczyk, Carisi Anne |
author_role |
author |
author2 |
Ferreira, Maria Angelica Pires Xavier, Cilene da Silva Souza, Ires Tarsila Alves de Cruz, Luciane Nascimento Polanczyk, Carisi Anne |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Batista, Joanna d'Arc Lyra Ferreira, Maria Angelica Pires Xavier, Cilene da Silva Souza, Ires Tarsila Alves de Cruz, Luciane Nascimento Polanczyk, Carisi Anne |
dc.subject.por.fl_str_mv |
Sistema Único de Saúde Saúde da criança Palivizumab Vírus sinciciais respiratórios Infecções por vírus respiratório sincicial |
topic |
Sistema Único de Saúde Saúde da criança Palivizumab Vírus sinciciais respiratórios Infecções por vírus respiratório sincicial Respiratory syncytial viruses Infant health Comparative effectiveness research |
dc.subject.eng.fl_str_mv |
Respiratory syncytial viruses Infant health Comparative effectiveness research |
description |
Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021 |
dc.date.accessioned.fl_str_mv |
2022-07-28T04:46:52Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/other |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/245656 |
dc.identifier.issn.pt_BR.fl_str_mv |
0036-4665 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001145970 |
identifier_str_mv |
0036-4665 001145970 |
url |
http://hdl.handle.net/10183/245656 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo. São Paulo. Vol. 63 (2021), e5, 8 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/245656/2/001145970.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/245656/1/001145970.pdf |
bitstream.checksum.fl_str_mv |
aba3e1b1bd65980c4ff06e1b54c1eb0c d9bb8533e2f02fb8318e438f8caa8384 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225062735413248 |